Mina Alpha Limited   Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2012)

Organization Overview

First Clinical Trial
2016
NCT02716012
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Mina Alpha Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

mtl-cebpa (3 trials)

sorafenib (nexavar) (1 trial)

Drugs in Phase 1 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3